Africa HIV Drugs Market Research Report: Forecast (2024-2030)

Africa HIV Drugs Market Report - By Drug Class (Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors, Integrase Inhibitors... ... Integrase Inhibitors, Fusion Inhibitors-Vector, Coreceptor Antagonists, Combination HIV Drugs, Others (Pharmacokinetic Enhancers, Capsid Inhibitors, etc.)), By Route of Administration (Oral Drugs, Injectable Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others Read more

  • Healthcare
  • May 2024
  • 167
  • PDF, Excel, PPT

Market Definition

HIV drugs are medications used to treat HIV infection by suppressing the replication of the virus in the body. These drugs target different stages of the HIV lifecycle, such as entry into cells, reverse transcription, integration into the host cell genome, and viral assembly and release. By inhibiting viral replication, HIV drugs help to reduce viral load, prevent the progression of HIV to AIDS, improve immune function, and prolong the lifespan of individuals living with HIV.

Market Insights & Analysis: Africa HIV Drugs Market (2024-30):

The Africa HIV Drugs Market size is estimated to grow at a CAGR of around 8.20% during the forecast period, i.e., 2024-30. The market growth has been attributed to sustainable economic growth and poverty reduction efforts that contributed to improved access to healthcare services, including HIV treatment. Africa has a large and growing population, with a high prevalence of HIV/AIDS compared to other regions. For instance,

  • According to the World Health Organization (WHO), in 2022, about 25.6 million people were living with HIV in the African region, among which around 760,000 were newly infected with HIV.
Report Coverage Details
Study Period Historical Data: 2019-22
Base Year: 2023
Forecast Period: 2024-30
CAGR (2024-2030) 8.20%
Country Covered South Africa, Nigeria, Kenya, Algeria, Uganda, Rest of Africa
Key Companies Profiled Aurobindo Pharma, ViiV Healthcare group of companies, Johnson & Johnson Services, Inc., Merck & Co., Inc., Cipla Inc., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences, Inc., Aspen Holdings, Cosmos Limited, and others
Unit Denominations USD Million/Billion

 

Hence, this demographic factor alone has been creating a sustained demand for HIV medications across African countries during historical years. Moreover, the rising investments in healthcare facilities, clinics, and supply chains to ensure reliable access to HIV medications and services in remote and underserved areas of the region are also likely to accelerate the growth & expansion of the Africa HIV Drugs Market. Further, the collaborative efforts taken by the key companies to improve access to HIV medications in Africa are also expected to positively impact overall market growth & expansion. For instance,

  • In 2023, GSK signed deals with Aurobindo Pharma, Cipla, and Viatris, allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine cabotegravir for use in lower-income countries, including South Africa, where the majority of new HIV cases occur.

  1. Market Segmentation
  2. Introduction
    1. Product Definition
    2. Research Process
    3. Assumptions
  3. Executive Summary
  4. Africa HIV Drugs Market Trends & Developments
  5. Africa HIV Drugs Market Dynamics
    1. Drivers
    2. Challenges
  6. Africa HIV Drugs Market Hotspot & Opportunities
  7. Africa HIV Drugs Market Regulations and Policy
  8. Africa HIV Drugs Market Patent Landscape
  9. Africa HIV Drugs Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Size & Analysis
      1. By Drug Class
        1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)- Market Size & Forecast 2019-2030, USD Million
        2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)- Market Size & Forecast 2019-2030, USD Million
        3. Protease Inhibitors- Market Size & Forecast 2019-2030, USD Million
        4. Integrase Inhibitors- Market Size & Forecast 2019-2030, USD Million
        5. Fusion Inhibitors-Vector- Market Size & Forecast 2019-2030, USD Million
        6. Coreceptor Antagonists- Market Size & Forecast 2019-2030, USD Million
        7. Combination HIV Drugs- Market Size & Forecast 2019-2030, USD Million
        8. Others (Pharmacokinetic Enhancers, Capsid Inhibitors, etc.)- Market Size & Forecast 2019-2030, USD Million
      2. By Route of Administration
        1. Oral Drugs- Market Size & Forecast 2019-2030, USD Million
        2. Injectable Drugs- Market Size & Forecast 2019-2030, USD Million
      3. By Distribution Channel
        1. Hospital Pharmacies - Market Size & Forecast 2019-2030, USD Million
        2. Retail Pharmacies- Market Size & Forecast 2019-2030, USD Million
        3. Online Pharmacies- Market Size & Forecast 2019-2030, USD Million
      4. By Country
        1. South Africa
        2. Algeria
        3. Nigeria
        4. Kenya
        5. Uganda
        6. Rest of Africa
      5. By Competition
        1. Competition Characteristics
        2. Market Share of Companies
  10. South Africa HIV Drugs Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Drug Class- Market Size & Forecast 2019-2030, USD Million
      2. By Route of Administration- Market Size & Forecast 2019-2030, USD Million
      3. By Distribution Channel- Market Size & Forecast 2019-2030, USD Million
  11. Algeria HIV Drugs Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Drug Class- Market Size & Forecast 2019-2030, USD Million
      2. By Route of Administration- Market Size & Forecast 2019-2030, USD Million
      3. By Distribution Channel- Market Size & Forecast 2019-2030, USD Million
  12. Nigeria HIV Drugs Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Drug Class- Market Size & Forecast 2019-2030, USD Million
      2. By Route of Administration- Market Size & Forecast 2019-2030, USD Million
      3. By Distribution Channel- Market Size & Forecast 2019-2030, USD Million
  13. Kenya HIV Drugs Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Drug Class- Market Size & Forecast 2019-2030, USD Million
      2. By Route of Administration- Market Size & Forecast 2019-2030, USD Million
      3. By Distribution Channel- Market Size & Forecast 2019-2030, USD Million
  14. Uganda HIV Drugs Market Outlook, 2019-2030F
    1. Market Size & Analysis
      1. By Revenues (USD Million)
    2. Market Share & Analysis
      1. By Drug Class - Market Size & Forecast 2019-2030, USD Million
      2. By Route of Administration- Market Size & Forecast 2019-2030, USD Million
      3. By Distribution Channel- Market Size & Forecast 2019-2030, USD Million
  15. Africa HIV Drugs Market Key Strategic Imperatives for Growth & Success
  16. Competitive Outlook
    1. Company Profiles 
      1. Aurobindo Pharma
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      2. ViiV Healthcare group of companies
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      3. Johnson & Johnson Services, Inc.
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      4. Merck & Co., Inc.
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      5. Cipla Inc. 
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      6. Bristol-Myers Squibb Company
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      7. AbbVie Inc. 
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      8. Gilead Sciences, Inc.
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      9. Aspen Holdings
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      10. Cosmos Limited
        1. Business Description
        2. Product Portfolio
        3. Strategic Alliances or Partnerships
        4. Recent Developments
        5. Financial Details
        6. Others
      11. Others
  17. Disclaimer


MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

Data Trangulation

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

We’d love to understand what matters most to you.

Your data is 100% confidential & secure

By submitting, you agree to our Terms and Privacy Policy .